Organogenesis is a leading regenerative medicine company focused on empowering healing through the development, manufacturing and sale of products for the advanced wound care, and surgical and sports medicine markets.


Our mission is to provide an integrated portfolio of healing solutions that improve lives while lowering the overall cost of health care. We are relentless in the pursuit of quality and innovations that make all the difference.

Areas of Focus

Advanced Wound Care

Our advanced wound care products are designed for the treatment of chronic and acute wounds. We offer a comprehensive portfolio of regenerative medicine products capable of supporting patients from early in the wound healing process through to wound closure, regardless of wound type.

Learn more

Surgical & Sports Medicine

Our surgical and sports medicine products support the healing of musculoskeletal injuries, including degenerative conditions such as osteoarthritis and tendonitis.

Learn more


Organogenesis was founded in 1985 as a spin-off of technology developed at the Massachusetts Institute of Technology (MIT). Our long and successful history of empowering healing began with the introduction of Apligraf®, the first and still the only living cell-based product that is FDA approved to treat both diabetic foot ulcers and venous leg ulcers. In 2014, our product portfolio expanded to include Dermagraft®, an FDA-approved therapy for the treatment of diabetic foot ulcers. The launch of our PuraPly® product line in 2015 gave clinicians new options for wound management across a variety of acute and chronic wound types. The introduction of PuraPly® Antimicrobial as an advanced wound care product has also addressed the growing need to manage bioburden and prevent biofilm reformation. In 2017, Organogenesis acquired NuTech Medical, which further expanded our product portfolio and introduced additional solutions for the advanced wound care market and enabled us to enter the surgical and sports medicine markets in a meaningful way.

Major Milestones

FDA approves Apligraf® for the treatment of venous leg ulcers.
FDA approves Apligraf® for the treatment of diabetic foot ulcers.
Launch of full U.S. sales and marketing organization.
European office established in Switzerland.
Acquires Dermagraft® for treatment of chronic diabetic foot ulcers.
Launches new PuraPly® product line.
Acquires NuTech Medical and expands product portfolio to include surgical and sports medicine.
ORGO began trading on the NASDAQ Stock Market.